Macrolides, Lincosamides, Quinolones, Tetracyclines and Other Antibacterials
On this page
01
Overview

02
Macrolides in detail
Macrolides bind the 50S subunit, blocking translocation — bacteriostatic at usual doses. They concentrate intracellularly, so they excel against atypical pathogens (Mycoplasma, Chlamydia, Legionella) and penetrate respiratory secretions.
Scroll the table sideways on a smaller screen.
| Drug | Adult dose (usual) | Paediatric dose | Main indications | Side & adverse effects | Contraindications & cautions | Counselling |
|---|---|---|---|---|---|---|
| Erythromycin (Watch) | 250–500 mg 6-hourly oral (base); IV per protocol. Atypical pneumonia, pertussis, campylobacteriosis | 10–12.5 mg/kg 6-hourly | Atypical pneumonia, pertussis (whooping cough), campylobacteriosis, chlamydial infection; gastric-motility stimulant (erythromycin low-dose) in feeding intolerance | GI upset and promotility effect (cramps, diarrhoea) via motilin; reversible cholestatic jaundice (class effect, esp. longer courses); QT prolongation (torsades risk); transient deafness at high dose/renal failure | QT-prolonging drugs or hypokalaemia (torsades); hepatic impairment; caution with statins (rhabdomyolysis — avoid simvastatin) | Take with food if nauseated but avoid heavy meals (reduces absorption); report palpitations, fainting, yellow eyes; complete course |
| Azithromycin (Watch) | 500 mg once daily ×3 days (or 500 mg day 1 then 250 mg days 2–5); single-dose 1 g for chlamydia (per STI guidelines) | 10 mg/kg once daily ×3 days | Atypical pneumonia, pertussis, chlamydial infection/STI syndromes, traveller's diarrhoea, trachoma (mass treatment), severe enteric fever alternative | Much better tolerated than erythromycin (no motilin stimulation); GI upset, rare QT prolongation, transient hearing change at high cumulative dose | QT-prolongation risk as above; macrolide allergy | Short course aids adherence; avoid antacids within 2 h (aluminium/magnesium reduce absorption) |
| Clarithromycin (Watch) | 250–500 mg 12-hourly ×7–14 days | 7.5 mg/kg 12-hourly | H. pylori eradication (combination), atypical pneumonia, sinusitis/otitis second line, nontuberculous mycobacteria (specialist) | GI upset, taste disturbance (metallic — characteristic), QT prolongation | As azithromycin; strong CYP3A4 inhibitor | Taste change is expected and resolves; avoid statins; report palpitations |
03
Lincosamides: clindamycin
Clindamycin also binds the 50S subunit (adjacent site) and is the key lincosamide. It achieves excellent bone, skin and abscess penetration and covers anaerobes and most streptococci/staphylococci (MRSA included in many regions) — but not enteric Gram-negatives.
Scroll the table sideways on a smaller screen.
| Item | Details |
|---|---|
| Dose | Adult 150–450 mg 6–8-hourly oral; severe 600 mg–1.2 g IV q8h. Child: 10–30 mg/kg/day divided q6–8h |
| Indications | Staphylococcal/streptococcal skin and soft-tissue infection, toxin suppression in streptococcal toxic shock and necrotising fasciitis (with a cell-wall agent), anaerobic infection above the diaphragm, dental abscess (penicillin-allergic), severe malaria adjunct (quinine combinations) per national guidance |
| Adverse effects | Clostridioides difficile colitis — the signature risk (disrupts colon flora); diarrhoea must trigger review and a C. difficile test; rash, oesophagitis (take with water, stay upright 30 min) |
| Contraindications / cautions | Prior C. difficile colitis; previous clindamycin-associated colitis; hepatic impairment (dose-adjust); not for meningitis or UTI (poor CSF/urine penetration) |
| Resistance note | Constitutive erm-mediated MLSB resistance → inducible clindamycin resistance in some staphylococci — severe streptococcal disease should get a macrolide-lincosamide-streptogramin B (D-zone/MLS) assessment where available |
04
Quinolones in detail
Quinolones inhibit DNA gyrase (topoisomerase II) and topoisomerase IV, preventing supercoil relaxation and bacterial replication — bactericidal, concentration-dependent. Fluorinated derivatives ("fluoroquinolones") have the Gram-negative power.
Scroll the table sideways on a smaller screen.
| Drug | Adult dose (usual) | Paediatric dose | Main indications | Side & adverse effects | Contraindications & cautions | Counselling |
|---|---|---|---|---|---|---|
| Ciprofloxacin (Watch) | Dysentery/shigellosis: 500 mg 12-hourly ×3 days. Complicated UTI/pyelonephritis: 500–750 mg 12-hourly. Typhoid (sensitive or with susceptibility): 500 mg 12-hourly; severe 400 mg IV q8–12h | Generally reserved for children (cartilage caution): 10–15 mg/kg 12-hourly for dysentery, short courses | Dysentery (first line per UCG for bloody diarrhoea), travel/complicated UTI, enteric fever, cholera adjunct, Gram-negative sepsis (with a beta-lactam), anthrax (post-exposure) | Nausea, diarrhoea, headache, dizziness; tendinitis and tendon rupture (Achilles — stop at first tendon pain); QT prolongation; dysglycaemia (rare); C. difficile; peripheral neuropathy (rare); chelation by antacids/iron/zinc/calcium/dairy — markedly reduces absorption | Pregnancy and breastfeeding (cartilage); children except specific short-course indications; epilepsy (lowers seizure threshold at high dose); QT-prolonging drugs; myasthenia gravis exacerbation; avoid concomitant tizanidine | Take with water, 2 h away from antacids, iron, zinc, calcium and dairy; report tendon pain, palpitations, severe diarrhoea; complete course; avoid excessive sun |
| Levofloxacin (Watch) | 500 mg once daily ×7–14 days (CAP, UTI per susceptibility) | 8–10 mg/kg once daily (selected indications) | Community-acquired pneumonia (including penicillin-resistant pneumococcus), complicated UTI, TB second-line (fluoroquinolone class) | Same class profile; prominent QT prolongation; insomnia and agitation reported | As ciprofloxacin | As ciprofloxacin; report new confusion or palpitations |
05
Tetracyclines in detail
Tetracyclines bind the 30S subunit, blocking amino-acyl-tRNA docking — bacteriostatic, broad-spectrum (including atypicals, rickettsiae, spirochaetes), and exceptionally well distributed into tissues.
Scroll the table sideways on a smaller screen.
| Item | Details |
|---|---|
| Dose | Adult 100 mg 12-hourly (day 1 may be 200 mg); many courses 7–14 days. Child >8 years: 2–4 mg/kg/day divided 12-hourly (short courses >8 y and <45 kg per protocol) |
| Indications | Atypical pneumonia, chlamydia (and syphilis alternative — 100 mg bd ×14 days if penicillin-allergic), rickettsioses (tick-borne relapsing fever), brucellosis (combination), acne, rosacea, chloroquine-resistant malaria prophylaxis, some cholera adjunct regimens |
| Side & adverse effects | Oesophagitis/ulceration (take with water, upright), nausea, photosensitivity (sunburn on exposure — counsel), Candida overgrowth; benign intracranial hypertension (rare); permanent teeth staining and growth effects in children <8 years and in the fetus (third trimester) |
| Contraindications / cautions | Pregnancy and breastfeeding; children <8 years (except short courses for rickettsiosis where benefit outweighs); severe hepatic impairment (large IV doses) |
| Interactions | Chelation: antacids, iron, calcium, magnesium, zinc and dairy slash absorption — separate by 2–3 h; warfarin potentiation (monitor INR); reduced efficacy of oral contraceptives during vomiting/diarrhoea |
06
Chloramphenicol, nitrofurantoin and metronidazole
Scroll the table sideways on a smaller screen.
| Drug | Dose (adult / child) | Indications | Side & adverse effects | Contraindications / counselling |
|---|---|---|---|---|
| Chloramphenicol (Access) | Adult 500 mg–1 g 6-hourly (meningitis per UCG: 1 g q6h); child 25–50 mg/kg/day divided q6h (meningitis 100 mg/kg/day). Eye drops for conjunctivitis | Bacterial meningitis when ceftriaxone unavailable (with benzylpenicillin per UCG), typhoid (sensitive strains, alternative), rickettsioses, eye infection (topical) | Aplastic anaemia (idiosyncratic, dose-independent, ~1:25,000 — the feared late effect), grey baby syndrome in neonates (immature glucuronidation → circulatory collapse — avoid in the newborn), dose-related marrow suppression (reversible), optic neuritis | Avoid in neonates (grey baby) and pregnancy near term; check FBC on courses >14 days; never for trivial infections; report bruising, sore throat, pallor |
| Nitrofurantoin (Access) | Simple UTI (cystitis): 100 mg 12-hourly ×5–7 days; prophylaxis 50–100 mg at night. Child: 5–7 mg/kg/day divided q6h | Lower UTI only — achieves high urinary but poor tissue levels | Nausea (common — take with food), orange-brown urine (harmless — counsel), peripheral neuropathy (renal impairment), rare pulmonary reactions and hepatitis; haemolysis in G6PD deficiency | Only if cystitis confirmed (never pyelonephritis — inadequate tissue levels); avoid in renal impairment (CrCl <30–45 mL/min) and G6PD deficiency; take with food and fluids |
| Metronidazole (Access) | Adult 400–500 mg 8-hourly ×7 days (amoebiasis, giardiasis, trichomoniasis); anaerobic infection 500 mg 8-hourly IV; C. difficile 400–500 mg 8-hourly ×10–14 days. Child 7.5–15 mg/kg 8-hourly | Protozoa (amoebiasis, giardiasis, trichomoniasis — see antiparasitic posts) and anaerobic bacteria (intra-abdominal/pelvic sepsis, dental abscess, C. difficile, H. pylori component) | Metallic taste, nausea, furry tongue, dark urine; peripheral neuropathy (prolonged courses); disulfiram-type reaction with alcohol (flushing, vomiting, tachycardia — avoid alcohol during and 48 h after); encephalopathy at high cumulative doses | Avoid alcohol during and 48 h after the course; warfarin potentiation (monitor INR); caution in hepatic impairment |
07
Cross-cutting interactions and counselling
Scroll the table sideways on a smaller screen.
| Class | Interaction | Effect & action |
|---|---|---|
| Macrolides (esp. erythromycin, clarithromycin) | Statins (simvastatin), theophylline, carbamazepine, warfarin, CYP3A4 substrates | CYP3A4 inhibition raises substrate levels — rhabdomyolysis with simvastatin (avoid combination), theophylline toxicity, raised INR; QT-additive with amiodarone, sotalol, fluconazole, antipsychotics |
| Quinolones | Antacids, iron, zinc, calcium, dairy; NSAIDs (seizures); warfarin; QT drugs | Chelation — separate by ≥2–4 h; NSAIDs lower seizure threshold; monitor INR; avoid QT stacking |
| Tetracyclines | Antacids/iron/calcium (chelation); warfarin; retinoids (benign intracranial hypertension) | Separate by 2–3 h; monitor INR; avoid isotretinoin co-prescription |
| Metronidazole | Alcohol; warfarin; lithium | Disulfiram reaction — counsel abstinence 48 h beyond the course; raised INR; raised lithium |
08
Clinical scenarios
Scenario 1 — Atypical pneumonia in a young adult
A 20-year-old student has 2 weeks of dry cough, low-grade fever and headache; chest X-ray shows patchy consolidation. The insidious course and absent toxic appearance suggest Mycoplasma pneumoniae. You treat with azithromycin 500 mg daily ×3 days (or doxycycline 100 mg bd ×7 days — both cover atypicals), counsel to report palpitations (QT), and advise returning if breathlessness worsens. A beta-lactam would have failed — Mycoplasma has no cell wall: a classic application of the targets map.
Scenario 2 — Bloody diarrhoea at the health centre
A 6-year-old has fever and bloody, mucoid stools — dysentery, most likely shigellosis. Per UCG you give ciprofloxacin (child: short-course per protocol) plus ORS and zinc, and counsel the mother to separate the dose from any antacid or iron by 2 hours. Three days later the child is well. The stewardship lesson: quinolones are justified here (invasive bacterial diarrhoea) — not for watery viral diarrhoea, where they add only risk.
Scenario 3 — Clindamycin and the warning diarrhoea
A 45-year-old on day 4 of clindamycin for a staphylococcal skin abscess develops profuse watery diarrhoea and cramping. You suspect C. difficile colitis, stop the clindamycin, send a stool test, start metronidazole (or oral vancomycin per protocol) if confirmed, and isolate as infection-control dictates. The teaching point: any antibiotic can cause it, but clindamycin, fluoroquinolones and broad-spectrum cephalosporins are the classic culprits — counsel patients at the start, not after.
09
Key points
10
References
- WHO AWaRe Antibiotic Book, 2022/2023 — atypical pneumonia, dysentery and STI regimens (Library reference.)
- Uganda Clinical Guidelines 2023: STI, diarrhoeal disease and meningitis chapters (Library reference.)
- Uganda Essential Medicines and Health Supplies List 2023 (Library reference.)
- Katzung's Basic & Clinical Pharmacology — macrolide, quinolone and tetracycline chapters (Library reference.)
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (Library reference.)
11
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and pharmaceutical organisations.
- WHO: The AWaRe Antibiotic Book
- Uganda MoH Knowledge Management Portal (UCG 2023 & EMHSLU 2023)
- US FDA: Fluoroquinolone safety communications (tendon, QT, neuropathy)
- DCM Year One Semester Two curriculum
For education only. Doses change with guideline updates — always verify against the current Uganda Clinical Guidelines, the EMHSLU 2023 and your facility formulary before prescribing.